Kent Davies Email and Phone Number
Kent Davies work email
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
Kent Davies personal email
- Valid
- Valid
Kent Davies phone numbers
Transformational business leader with an exceptional record of accelerating organic growth and innovation, delivering operational performance, and creating transactional value at leading public and private-equity sponsored businesses.- More than 20 years of board-level interaction with multi-billion-dollar public companies and PE funds. Operating advisor to ARCHIMED. Board of Directors at Irrimax Corp. Member of the Healthcare Advisory Roundtable with Madison Dearborn Partners, LLC. Served as Director, HIDA Educational Foundation and on the Boards of Directors of Nautic Partners' HB Performance Systems, Inc. and Gaymar Holdings, LLC. and multiple other corporate operating entities in the U.S., Europe, and Asia.- President & Chief Operating Officer of PDI, scaling the recognized infection prevention products & services leader from $300 million to nearly $500 million, leveraging accelerated organic growth, technology partnerships, and acquisitions while building operational discipline and delivering results.- Responsible for $910 million P&L as Chief Operating Officer of Haemonetics, guiding the company through a complex strategy, leadership, and performance reset to accelerate growth and value creation.- CEO of RoundTable Platform Development Corporation, leading a novel strategy, transaction sourcing, and pipeline development initiative for RoundTable Healthcare Partners' $600MM Fund III.- As CEO-elect, provided strategic and operational guidance to private-equity sponsors during the sale of Sterilmed, Inc. to J&J’s Ethicon Endo-Surgery, at 42x EBITDA.- Delivered double-digit top-line growth and a 47% increase in EBITDA as CEO of Gaymar Industries while leading its sale to Stryker Corp.- Accelerated organic and transactional growth to build United Industries from $265 million to $1.1 billion over four years.- Grew Kimberly-Clark’s healthcare business from $300 million to $1 billion over just four years.More than 25 years of multi-functional leadership in the U.S., EMEA, Asia, and other emerging markets. Recruited and developed diverse and talented leadership teams at multiple companies.Seasoned multi-functional leader with extensive private equity operating, change leadership, carve-out, and restructuring experience. Significant experience with equity analysts and investors at multiple NYSE-listed companies.
-
Operating Partner And Portfolio Company Board ChairArchimedBoston, Ma, Us
-
Independent Board Member & Operating AdvisorActive, Pe-Focused Board Member & Advisor 2023 - PresentCurrently engaged as an operating advisor to ARCHIMED, leading the separation / carve-out of their >$500MM Natus Medical, into two independent Neuro and Audiology device, disposables, and services platforms and facilitating deployment of ~$8.5 billion in capital across multiple, rapidly expanding, global, med-tech funds.Board of Directors of Irrimax Corp., a market leader in antimicrobial wound irrigation solutions.Member of the Healthcare Advisory Roundtable with Madison Dearborn Partners.Seven, multi-phase, buy-side advisory engagements since 2023 with clients including Brookfield Capital Partners, Madison Dearborn Partners, Vestar Capital, and Water Street Healthcare Partners.
-
President & Chief Operating OfficerPdi 2017 - 2022Woodcliff Lake, New Jersey, UsLed the accelerated growth and development of this innovative infection prevention products & services platform, addressing complex needs for clinical efficacy, cost efficiency, and valued services across a large and growing global market.Advanced ambitious strategy of organic innovation, market segment & geographic expansion, in-organic partnerships, and acquisitions, while investing in operational excellence, back-office productivity, and business process automation.Scaled business from $300 million to nearly $500 million. More than tripled the inherited organic growth rate, while closing and integrating two portfolio broadening acquisitions. Grew net sales by ~50% and EBITDA by 67% over three years, as the market and platform expanded.Doubled the size of the food safety business, including 25% top-line growth in 2022, while significantly enhancing its margin, as part of a successful channel expansion initiative.Leveraged pricing, "lean" cost savings, and overhead improvements to combat rising input and supply chain costs.Recruited and developed a strong leadership team including new CFO, CHRO, SVP Corporate Development, SVP R&D, VP RA/QA, and North American and Global Commercial leaders, while doubling the size of the independent Board. -
Chief Operating OfficerHaemonetics 2014 - 2016Boston, Ma, UsFull P&L responsibility for NYSE-listed blood and plasma market leader that reported nearly $910 million in FY16 revenue. Spearheaded corporate portfolio strategy and value creation initiative, attacked legacy cost structure, and reoriented from regional / revenue-driven business model to global, product, technology, and end-market focus. Grew market-leading plasma collection business by more than 30%, while reinventing the global market standard for plasma collection hardware, software, and disposables systems.Grew highly-differentiated blood diagnostic platform by more than 50%; launched innovative TEG® 6s hemostasis analyzer, cartridge-based reagent system, and TEG Manager™ connectivity software addressing $1.5 billion market opportunity in the U.S., China, and EMEA.Comprehensively rebuilt the general management and portfolio leadership functions driving growth and change through the company’s four multi-functional Presidents in the Americas, EMEA, Japan, and greater Asia. Developed and implemented new product lifecycle process to accelerate growth through R&D.Initiated off-shoring of back-office functions while manufacturing refocused on lower-cost internal supply and third-party sourcing model.Significant board and committee interaction and frequent interface with equity analysts and institutional investors. -
CeoRoundtable Platform Development Corporation 2012 - 2014Led medical device strategy, transaction sourcing, and pipeline development initiative for RoundTable Healthcare Partners’ $600 million Fund III. RoundTable is an operationally-oriented private equity firm with $4.25 billion under management.
-
Ceo (Elect)Sterilmed 2011 - 2011Hired as CEO of rapidly-growing medical device and services company. Provided strategic and operational guidance to private-equity sponsors during transaction process that yielded a successful sale of Sterilmed to J&J’s Ethicon Endo-Surgery, at 42x EBITDA. -
Ceo, Gaymar IndustriesStryker 2009 - 2011Kalamazoo, Mi, UsCEO and board member of private-equity sponsored medical device and services company whose 400 employees and three production facilities developed, manufactured, and marketed clinically-proven products for the pressure ulcer management and temperature management markets worldwide.Delivered double-digit top-line growth and a 47% increase in EBITDA while significantly improving cash performance and substantially reducing debt. Rebuilt executive leadership team. Quickly defined corporate growth, business development, and technology strategy. Redesigned manufacturing process flow, reduced variable costs, and improved productivity, yielding 360 basis points of gross margin improvement.Attracted a strategic buyer and led the high-value sale of Gaymar Industries to Stryker Corp. Facilitated successful integration. -
President, Cpfilms, Inc. & Senior Vice PresidentSolutia 2006 - 2009Division president and top-five corporate officer of $4 billion, specialty chemicals and performance materials company that delivered 50% revenue growth and 170% profit growth through four-year restructuring.Provided multi-functional leadership for world’s largest manufacturer and marketer of after-market window films, improving segment mix and profitability while leading global growth and developing rapidly-growing thin-film-technology business. Drove transformation and growth of $250 million brand, product, and channel-driven business with four manufacturing facilities, multiple distribution centers, and 750 employees worldwide.Utilized “lean” techniques to create significantly more efficient and more profitable manufacturing processes to support business growth. Tripled sales and gross profit growth. Delivered eight consecutive quarters of gross margin and working capital improvements. Grew EBITDA by 30%. Nearly doubled cash flow and ROIC. Active participant at board, analyst, and investor meetings. Successfully listed new equity on the NYSE.
-
Senior Vice President, Marketing, R&D And RegulatoryUnited Industries Corp. 2001 - 2005One of four corporate officers and senior operating executives responsible for executing the organic growth and acquisition strategy to successfully consolidate the U.S. consumer lawn & garden and household insect control markets.Grew revenue from $265 million to $1.1 billion over four years while integrating six acquisitions, launching innovative new products, and taking market share from larger competitors.Facilitated successful exit for private equity owners.
-
Various Global General Management, Strategic Marketing, And Product Management RolesKimberly-Clark 1994 - 2001Irving, Tx, UsDrove organic revenue expansion at two times the market rate and successfully integrated three acquisitions as part of management team that grew the K-C’s Professional Healthcare business from $300 million to $1 billion over four years. Lived and worked in Brussels, Belgium as expat leader of K-C’s European healthcare business. Ultimately, responsible for $600 million P&L, leading medical device and infection prevention platforms in the U.S., Europe, and Japan. -
Various Global Strategic Marketing And Product Management Roles3M 1991 - 1994St Paul, Mn, UsGenerated share and revenue growth for one of 3M Healthcare’s largest and most profitable SBUs. -
Various Sales & Sales Management RolesGeneral Mills 1989 - 1991Minneapolis, Minnesota, Us
Kent Davies Skills
Kent Davies Education Details
-
University Of California, BerkeleyHistory -
University Of Minnesota - Carlson School Of ManagementMarketing
-
The Wharton SchoolExecutive Education Courses In Finance And Accounting (1996 - 1997)
Frequently Asked Questions about Kent Davies
What company does Kent Davies work for?
Kent Davies works for Archimed
What is Kent Davies's role at the current company?
Kent Davies's current role is Operating Partner and Portfolio Company Board Chair.
What is Kent Davies's email address?
Kent Davies's email address is kd****@****ics.com
What is Kent Davies's direct phone number?
Kent Davies's direct phone number is +171666*****
What schools did Kent Davies attend?
Kent Davies attended University Of California, Berkeley, University Of Minnesota - Carlson School Of Management, The Wharton School.
What skills is Kent Davies known for?
Kent Davies has skills like Business Development, Business Strategy, Change Management, Commercialization, Competitive Analysis, Corporate Development, Cross Functional Team Leadership, Finance, Global Marketing, Integrated Marketing, Leadership, Management.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial